<DOC>
	<DOCNO>NCT01631071</DOCNO>
	<brief_summary>The study ass whether virosomal influenza vaccine season 2012/2013 fulfills EMA requirement re-registration influenza vaccine .</brief_summary>
	<brief_title>Re-licensing Study Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy female male adult age ≥18 Day 1 Written inform consent Female subject childbearing potential use willing continue use acceptable method contraception unless surgically sterilized/hysterectomized postmenopausal 2 year Acute exacerbation bronchopulmonary infection ( cough , sputum , lung finding ) acute disease Acute febrile illness ( ≥38.0 °C ) Prior vaccination influenza vaccine past 330 day Known hypersensitivity vaccine component Previous history serious adverse reaction influenza vaccine History egg protein allergy severe atopy Known blood coagulation disorder Chronic ( longer 14 day ) administration immunosuppressant immunemodifying drug within 6 month first dose study vaccine , include oral corticosteroid dosage ≥0.5 mg/kg/d prednisolone equivalent ( inhaled topical steroid allow ) Known immunodeficiency ( incl . leukemia , HIV seropositivity ) , cancer Investigational medicinal product receive past 3 month ( 90 day ) start first day month follow last visit previous study Treatment immunoglobulins blood transfusion ( ) receive past 3 month ( 90 day ) Pregnancy lactation Participation another clinical trial Employee investigational site , relative investigator Subjects view investigator comply study procedure and/or visit requirement per protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Virus</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Virosomal influenza vaccine</keyword>
</DOC>